Sana Biotechnology, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Sana Biotechnology, Inc. (SANA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $2.04 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-10
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $2.04, a 5.15% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.94, a 55.91% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $4.40, a 199.32% increase year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $1.47, a 34.96% decline year-over-year.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $2.19, a 39.00% decline from fiscal 2024.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $3.59, a 101.69% increase from fiscal 2023.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $1.78, a 15.24% decline from fiscal 2022.
- Sana Biotechnology, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $2.10, a 5.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.04 10-Q · filed 2026-08-10 | |||
| 2026-03-31 | $2.04 10-Q · filed 2026-05-11 | |||
| 2025-12-31 | $2.19 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $1.89 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $1.87 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $1.94 10-Q · filed 2025-05-08 | |||
| 2024-12-31 | $3.59 10-K · filed 2025-03-17 | |||
| 2024-09-30 | $3.72 10-Q · filed 2024-11-08 | |||
| 2024-06-30 | $4.38 10-Q · filed 2024-08-08 | |||
| 2024-03-31 | $4.40 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $1.78 10-K · filed 2024-02-29 | |||
| 2023-09-30 | $1.78 10-Q · filed 2023-11-08 | |||
| 2023-06-30 | $1.76 10-Q · filed 2023-08-03 | |||
| 2023-03-31 | $1.47 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $2.10 10-K · filed 2023-03-16 | |||
| 2022-09-30 | $2.16 10-Q · filed 2022-11-02 | |||
| 2022-06-30 | $2.02 10-Q · filed 2022-08-04 | |||
| 2022-03-31 | $2.26 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | $2.00 10-K · filed 2022-03-16 | |||
| 2021-09-30 | $1.99 10-Q · filed 2021-11-08 | |||
| 2021-06-30 | $1.58 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $1.35 10-Q · filed 2021-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |